BioCentury
ARTICLE | Product Development

AACR data suggest Agenus’ next-generation CTLA-4 blocker may expand responding patient group

April 12, 2021 10:21 PM UTC

Agenus’ latest clinical data for AGEN1181 support the idea that Fc engineering can expand the population of patients who respond to checkpoint inhibitors. 

While many companies are searching for the next checkpoint target to help treat patients who don’t respond to first-generation PD-1 or CTLA-4 blockers, or who relapse after treatment, others including Agenus Inc. (NASDAQ:AGEN) are putting resources toward next-generation compounds against the validated checkpoint targets. ...